- |||||||||| Review, Journal, HEOR, Checkpoint inhibition, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review. (Pubmed Central) - Jul 5, 2024
The current evidence showed that ICIs, including atezolizumab plus bevacizumab, sintilimab plus bevacizumab/bevacizumab biosimilar, nivolumab, camrelizumab plus rivoceranib, pembrolizumab plus lenvatinib, tislelizumab, durvalumab, and cabozantinib plus atezolizumab, are probably not cost-effective in comparison with tyrosine kinase inhibitors or other ICIs...Our review demonstrated that ICIs were not a cost-effective intervention in advanced HCC. Although ICIs can significantly enhance the survival of patients with advanced HCC, decision-makers should consider the findings of economic evaluations and affordability before adoption of new therapies.
- |||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Enrollment closed, Trial initiation date, Metastases: Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 2, 2024 P2, N=50, Active, not recruiting, Therefore, careful monitoring is required for potentially high-risk patients undergoing ICI combination therapy. Recruiting --> Active, not recruiting | Initiation date: Nov 2023 --> Jul 2023
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, Tumor microenvironment: Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment. (Pubmed Central) - Jul 1, 2024 The potent pan-FGFR/VEGFR inhibitor, Lenvatinib, uniformly induces tumor regression in AM patient-derived xenograft (PDX) tumors but only slows tumor growth in CM models...Considering the great difficulty in establishing AM cell culture lines, these findings suggest that AM may be more sensitive to microenvironment perturbations than CM. In conclusion, dual FGFR/VEGFR inhibition may be a viable therapeutic strategy that targets the unique biology of AM.
- |||||||||| Journal, Metastases: Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma. (Pubmed Central) - Jul 1, 2024
Using more potent immuno-checkpoint inhibitors (ICIs), at least 4 phase III trials of adjuvant immunotherapy are ongoing: nivolumab, durvalumab/ bevacizumab, pembrolizumab, and atezolizumab+bevacizumab...There are 2 neoadjuvant trials for technically or oncologically unresectable HCCs ongoing in Japan: the LENS-HCC trial using lenvatinib and the RACB study using atezolizumab+bevacizumab...They obtained a Japanese consensus on this issue that has been published on the websites of JLCA and JSHPBS. The definition of resectability or borderline resectability provides a common language regarding advanced HCC for investigators and is a useful tool for future clinical trials.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Expression of vascular endothelial growth factor receptor in thymic epithelial tumors. (Pubmed Central) - Jun 28, 2024 Lenvatinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, is approved as a drug therapy for thymic carcinoma (TC); however, although it is a molecular targeted therapy, there are no obvious predictors of therapeutic efficacy...Furthermore, the pathological stage was the only factor significantly associated with OS in multivariate analysis. The results of the present study suggest the possibility that the indications for VEGF inhibitor therapy could be extended to type B3 thymoma.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial withdrawal: Neo PeLeMM: Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (clinicaltrials.gov) - Jun 25, 2024 P2, N=0, Withdrawn, Combination lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-na N=44 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| Mekinist (trametinib) / Novartis, BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors (clinicaltrials.gov) - Jun 25, 2024 P2, N=100, Recruiting, Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Mar 2025 Trial completion date: Jan 2027 --> Jan 2037 | Trial primary completion date: Jan 2025 --> Jan 2029
- |||||||||| Trial completion date, Trial primary completion date, Metastases: MK-6482-012 China Extension: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study (clinicaltrials.gov) - Jun 21, 2024
P3, N=249, Active, not recruiting, Hepatitis B infection, liver cirrhosis, portal vein tumor thrombus, multiple tumors and large tumor diameter may be potential factors that affect the efficacy of PD-1 inhibitors but need further validation. Trial completion date: Jun 2027 --> Dec 2026 | Trial primary completion date: Jun 2027 --> Dec 2026
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, IO biomarker: Thyroid carcinomas: the role of systemic therapies in internal medicine (Pubmed Central) - Jun 20, 2024 Where molecular targets are lacking, combination therapy with the MKI lenvatinib and immune checkpoint inhibition is highly effective...In summary, thyroid carcinomas are among the tumour entities for which molecularly targeted therapies can be used most frequently. The involvement of specialised centres is advisable.
- |||||||||| Review, Journal, Metastases: Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. (Pubmed Central) - Jun 19, 2024
This review highlights the efficacy of multikinase inhibitors and immune checkpoint inhibitors in monotherapy and combination therapy through the analysis of phase II, and III clinical trials, targeting the key molecular pathways involved in cellular signaling and immune response for the prospective treatment of advanced and unresectable HCC and discusses the upcoming combinations of immune checkpoint inhibitors-tyrosine kinase inhibitors and immune checkpoint inhibitors-vascular endothelial growth factor inhibitors. Finally, the hidden challenges with pharmacological therapy for HCC, feasible solutions for the future, and implications of possible presumptions to develop drugs for HCC treatment are reported.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date, Stroma, Metastases: LENVAGIST: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (clinicaltrials.gov) - Jun 18, 2024 P2, N=77, Completed, Meanwhile, circ_0007386 served as a potential biomarker and therapeutic target in HCC patients. Recruiting --> Completed | Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Jan 2024
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights. (Pubmed Central) - Jun 17, 2024 Despite the approval of immunotherapy in 2020, specifically the combination of atezolizumab and bevacizumab following the IMbrave150 trial, tyrosine kinase inhibitors remain an indispensable class of agents in the landscape of hepatocellular carcinoma treatment. This comprehensive review delves into various facets of lenvatinib utilization in hepatocellular carcinoma, shedding light on real-world data, addressing challenges, and providing insights into strategies to overcome these obstacles.
- |||||||||| limantrafin (CB-103) / Cellestia Biotech, Lenvima (lenvatinib) / Eisai, Merck (MSD), Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC (clinicaltrials.gov) - Jun 16, 2024 P1/2, N=34, Recruiting, This comprehensive review delves into various facets of lenvatinib utilization in hepatocellular carcinoma, shedding light on real-world data, addressing challenges, and providing insights into strategies to overcome these obstacles. Trial primary completion date: Jun 2024 --> Jun 2025
- |||||||||| Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date: CCGLC-013: Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Jun 13, 2024 P2, N=36, Recruiting, Therefore, in the future, combination therapy of lenvatinib with TACE could be potentially prioritized over sorafenib with TACE for the treatment of patients with uHCC. Initiation date: Jan 2024 --> Jun 2024
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Mismatch repair: Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer (clinicaltrials.gov) - Jun 12, 2024 P2, N=4, Active, not recruiting, Initiation date: Jan 2024 --> Jun 2024 Recruiting --> Active, not recruiting | N=100 --> 4 | Trial completion date: Sep 2035 --> Sep 2025 | Trial primary completion date: Sep 2025 --> Nov 2024
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, Metastases: Metastatic glioblastoma to the lungs: a case report and literature review. (Pubmed Central) - Jun 12, 2024 This case contributes to the growing body of evidence for the role of genomic alterations in predictive risk in metastatic glioblastoma. There remains an unmet need for treatment of metastatic glioblastoma.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: GPX4 transcriptionally promotes liver cancer metastasis via GRHL3/PTEN/PI3K/AKT axis. (Pubmed Central) - Jun 11, 2024 As AKT is a downstream target of GPX4, we combined the AKT inhibitor, AKT-IN3, with lenvatinib to effectively inhibit HCC tumor cell metastasis. Overall, these results indicate that the GPX4/GRHL3/PTEN/PI3K/AKT axis controls HCC cell metastasis and lenvatinib combined with AKT-IN3 represents a potential therapeutic strategy for patients with metastatic HCC.
|